{
"id":"mk19_a_id_s17",
"subspecialtyId":"id",
"title":"Health Care–Associated Infections",
"jsonContent":{
"type":"section",
"id":"mk19_a_id_s17",
"title":{
"__html":"Health Care–Associated Infections"
},
"titleNode":{
"type":"section-title",
"hlId":"fb6623",
"children":[
"Health Care–Associated Infections"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_id_s17_1",
"title":{
"__html":"Epidemiology"
},
"titleNode":{
"type":"section-title",
"hlId":"7113ad",
"children":[
"Epidemiology"
]
},
"children":[
{
"type":"p",
"hlId":"0c74aa",
"children":[
"Health care–associated infections (HCAI) have been linked to indwelling medical devices, prosthetic devices and materials, surgery, invasive procedures, transmission of organisms between patients and health care personnel, and environmental factors. Approximately 3.2% of hospitalized patients acquire at least one HCAI, costing the U.S. health care system an estimated $28 billion to $45 billion annually. HCAIs include pneumonia (25.8%), gastrointestinal infections (21.3%), surgical site infections (16.2%), bloodstream infections (12.2%; 73% associated with central venous catheters), and urinary tract infections (UTIs, 9.1%; 61.5% associated with catheters). ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Clostridioides difficile"
]
},
" is another common HCAI (see ",
{
"type":"cross-reference",
"target":"mk19_a_id_s15_8",
"children":[
"Infectious Gastrointestinal Syndromes"
]
},
"); the incidence has begun declining after unprecedented high rates, although community-acquired ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. difficile"
]
},
" continues to rise."
]
},
{
"type":"p",
"hlId":"9ced99",
"children":[
"Elimination of HCAIs remains important for the U.S. health care system. Thirty-five percent to 55% of HCAIs are considered preventable. Progress toward elimination varies by type of infection. Central line–associated bloodstream infections decreased by 19% and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. difficile"
]
},
" infections by 20% between 2015 and 2017; catheter-associated UTIs decreased by 5% between 2016 and 2017."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_2",
"title":{
"__html":"Prevention"
},
"titleNode":{
"type":"section-title",
"hlId":"c53b76",
"children":[
"Prevention"
]
},
"children":[
{
"type":"p",
"hlId":"cc2172",
"children":[
"Hand hygiene is the foundation of infection prevention, but less than 50% adherence has been reported. Most facilities have improved in the last decade, with sustained improvement up to 90% adherence at some facilities. Hand hygiene should be performed at least before and after every patient contact. The World Health Organization's five key hand hygiene moments (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.who.int/gpsc/tools/5momentsHandHygiene_A3.pdf?ua=1",
"target":"_blank"
},
"children":[
"https://www.who.int/gpsc/tools/5momentsHandHygiene_A3.pdf?ua=1"
]
},
") are commonly used to define hand hygiene opportunities. Hand hygiene should include all surfaces of the hands up to the wrists, between fingers, and the fingertips (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://youtu.be/IisgnbMfKvI",
"target":"_blank"
},
"children":[
"https://youtu.be/IisgnbMfKvI"
]
},
"). Alcohol-based hand rubs are generally preferred to soap and water hand disinfection, except when hands are visibly soiled, when personnel come in direct contact with blood or body fluids, or after contact with a patient with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. difficile"
]
},
" infection or his or her environment."
]
},
{
"type":"p",
"hlId":"c974e8",
"children":[
"Standard precautions should be practiced for every patient to protect health care personnel from exposure to bloodborne pathogens. Blood and all body fluids except sweat are potentially infectious, regardless of the patient's presumed or known infection status. Personal protective equipment (gloves, gown, mask, and eye protection) are barriers protecting health care personnel from exposure to blood and body fluids. Protective equipment should be donned and doffed carefully (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.cdc.gov/HAI/pdfs/ppe/ppeposter148.pdf",
"target":"_blank"
},
"children":[
"https://www.cdc.gov/HAI/pdfs/ppe/ppeposter148.pdf"
]
},
") and followed by hand hygiene. Transmission-based precautions (airborne, contact, droplet) are performed in addition to standard precautions to prevent transmission of epidemiologically significant organisms ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t53",
"wrapId":"1",
"children":[
"Table 53"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_a_id_t53"
]
},
{
"type":"p",
"hlId":"1ba60f",
"children":[
"Additional preventive measures include careful and judicious device use, safe injection practices (one needle, one syringe, only one time), aseptic technique for invasive procedures and surgery, and a clean environment and patient equipment. HCAI prevention “bundles” comprise three to five evidence-based processes of care that, when performed together, consistently have a greater impact on decreasing HCAIs than individual components performed inconsistently."
]
},
{
"type":"p",
"hlId":"8a404d",
"children":[
"All U.S. health care facilities are required to have an infection prevention program. The infection prevention team is responsible for providing the knowledge and recommending the means to minimize risks of acquiring an HCAI."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"cb5e24",
"hvc":true,
"children":[
"Hand hygiene is the foundation of infection prevention; the World Health Organization has identified five key hand hygiene moments (before touching a patient, before clean or aseptic procedure, after body fluid exposure risk, after touching a patient, and after touching patient surroundings)."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_3",
"title":{
"__html":"Catheter-Associated Urinary Tract Infections"
},
"titleNode":{
"type":"section-title",
"hlId":"7a9066",
"children":[
"Catheter-Associated Urinary Tract Infections"
]
},
"children":[
{
"type":"p",
"hlId":"0c41d3",
"children":[
"Seventeen percent to 69% of catheter-associated urinary tract infections (CAUTIs) may be preventable. Urinary catheters are used in 15% to 25% of hospitalized patients in the United States, compelling efforts to establish appropriateness criteria for catheter use. Adverse outcomes related to CAUTI include pyelonephritis, perinephric abscess, and bacteremia (<5%). ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Escherichia coli"
]
},
" is the most common CAUTI pathogen, followed by ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Klebsiella pneumoniae/Klebsiella oxytoca, Pseudomonas aeruginosa"
]
},
", and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Enterococcus"
]
},
" species; antibiotic resistance among these pathogens is increasing."
]
},
{
"type":"p",
"hlId":"001f06",
"children":[
"Colonization with bacteria or yeast occurs within 48 hours of catheterization. Duration of catheterization is the primary modifiable risk factor for CAUTI; each day increases the risk of CAUTI. Nonadherence to aseptic technique (for example, opening a closed system) and insertion by a less experienced operator also increase the risk. Patient-related risk factors include female sex, age older than 50 years, diabetes mellitus, severe or nonsurgical underlying illness, and serum creatinine level greater than 2.0 mg/dL (176.8 µmol/L). Appropriate indications for indwelling urinary catheters are listed in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t54",
"wrapId":"2",
"children":[
"Table 54"
]
}
]
},
". Management of urinary incontinence using external catheters is preferred when feasible. Provision of care in the ICU is not itself an indication for a catheter."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_a_id_t54"
]
},
{
"type":"section",
"id":"mk19_a_id_s17_3_1",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"f6a65d",
"children":[
"Patients with an indwelling urethral or suprapubic catheter (or catheter removed in the 48 hours before symptom onset) or using intermittent catheterization who have signs and symptoms compatible with UTI (see ",
{
"type":"cross-reference",
"target":"mk19_a_id_s5_2",
"children":[
"Urinary Tract Infections"
]
},
" for information), no other identifiable infection source, and 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"3"
]
},
" colony-forming units/mL or more of one or more bacterial species in a urine specimen are diagnosed with a CAUTI. Catheter-associated asymptomatic bacteriuria (≥10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"3"
]
},
" colony-forming units/mL without urinary tract signs or symptoms) is common and generally does not require treatment."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_3_2",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"df6d59",
"children":[
"Before initiating antimicrobial treatment, a urinalysis and urine culture should be obtained to determine if antimicrobial resistance is present and to guide definitive therapy. CAUTI management includes removing the urinary catheter (and only replacing if still needed). Removal is strongly recommended for catheters in place for 2 or more weeks because biofilm on the catheter makes it difficult to eradicate bacteriuria or funguria and may lead to antimicrobial resistance. Therapy should always be adjusted to the narrowest coverage spectrum possible based on culture results. Treatment is given for 5 to 7 days if symptoms resolve promptly and longer (10-14 days) for patients with delayed response. Candiduria in a patient with a catheter frequently represents colonization and rarely requires treatment. ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
" CAUTI is considered when significant candiduria persists despite catheter removal or replacement and the patient is symptomatic. CAUTIs caused by ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
" species requiring treatment should be treated for 14 days."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_3_3",
"title":{
"__html":"Prevention"
},
"titleNode":{
"type":"section-title",
"hlId":"c53b76",
"children":[
"Prevention"
]
},
"children":[
{
"type":"p",
"hlId":"1b0fc1",
"children":[
"Key prevention strategies include appropriately limiting urinary catheter use (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t54",
"wrapId":"3",
"children":[
"Table 54"
]
}
]
},
")"
]
},
" and considering other options associated with lower infection risk (intermittent straight catheterization, external catheters) when urine collection is necessary ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t55",
"wrapId":"3",
"children":[
"Table 55"
]
}
]
},
")"
]
},
". Most studies have not shown definitive benefit of antimicrobial- or antiseptic-coated catheters for short- (<14 days) or long-term catheterization; these catheters are more expensive and, in some cases (such as nitrofurazone-coated catheters), cause more patient discomfort."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_a_id_t54",
"mk19_a_id_t55"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"2750a3",
"hvc":true,
"children":[
"Catheter-associated asymptomatic bacteriuria is common and generally does not require treatment."
]
},
{
"type":"keypoint",
"hlId":"3c00f4",
"hvc":true,
"children":[
"Catheter-associated urinary tract infection management includes catheter removal, with replacement only if still necessary."
]
},
{
"type":"keypoint",
"hlId":"020bed",
"hvc":true,
"children":[
"Candiduria in a patient with a catheter frequently represents colonization and rarely requires treatment."
]
},
{
"type":"keypoint",
"hlId":"de2cf0",
"hvc":true,
"children":[
"Antimicrobial- or antiseptic-coated catheters have not shown benefit for short-term or long-term catheterization, are more expensive, and, in some cases, cause more discomfort for patients."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_4",
"title":{
"__html":"Surgical Site Infections"
},
"titleNode":{
"type":"section-title",
"hlId":"37606d",
"children":[
"Surgical Site Infections"
]
},
"children":[
{
"type":"p",
"hlId":"446d25",
"children":[
"Surgical site infections (SSIs) account for 23% of HCAIs. The overall risk of developing an SSI is 1.9%. Wound class affects the risk of infection, with clean wounds having less than a 2% risk of infection, clean contaminated wounds having less than a 10% risk, and contaminated wounds having a 20% risk. Most infections occur within 30 days after surgery or within 90 days after surgery with implants; however, infections can manifest beyond these ranges. Risk factors include patient-related, procedure-related, and postoperative factors ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t56",
"wrapId":"4",
"children":[
"Table 56"
]
}
]
},
")"
]
},
". The patient's skin and gastrointestinal or female genital tracts are major sources of organisms causing infection, depending on the type of surgery. The time during which the surgical site is open represents the period of greatest risk. Common SSI pathogens are ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus aureus"
]
},
" (23%), coagulase-negative staphylococci (17%), enterococci (7%), ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"E. coli"
]
},
" (5%), and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"P. aeruginosa"
]
},
" (5%). Exogenous sources of organisms (surgical personnel, surgical instruments, environment) are less common causes of SSIs, usually identified when a cluster of infections is present."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_a_id_t56"
]
},
{
"type":"section",
"id":"mk19_a_id_s17_4_1",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"0873e7",
"children":[
"Clinical signs and symptoms vary by infection site and type as well as by implicated organism (for example, some are more likely to cause purulence). Inflammatory changes at the surgical site (pain or tenderness, warmth, swelling, erythema) and purulent drainage suggest a superficial incisional infection. Deep incisional SSIs have more extensive tenderness expanding outside the area of erythema and more systemic signs, such as fever and leukocytosis. Wound dehiscence suggests a deep incisional SSI unless the wound or drainage is culture negative. Organ and deep-space SSIs are associated with more systemic signs and local symptoms related to a deep abscess or infected fluid collection. In cases of suspected organ or deep-space SSIs, CT is helpful to localize the infection and determine the best approach to fluid or abscess drainage for culture and treatment. When an SSI is suspected, drainage, purulent fluid, and infected tissue should be obtained for culture. Deep-tissue or wound cultures are preferable to superficial wound swab cultures that are likely to reflect skin or wound colonization and not necessarily yield the causative pathogen."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_4_2",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"6c32d8",
"children":[
"SSI treatment requires debridement of necrotic tissue, drainage of abscesses or infected fluid, and specific antimicrobial therapy for organ or deep-space and deep incisional infections. Repeat debridement or drainage may be required to control and resolve the infection even with appropriate antimicrobial therapy. When an SSI involves an implant, implant removal is preferred, followed by a prolonged course of antibiotics. Superficial incisional infections can usually be managed with oral antibiotics without tissue debridement. Culture results guide the choice of antimicrobial agent; treatment duration varies by anatomic site and by depth of infection."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_4_3",
"title":{
"__html":"Prevention"
},
"titleNode":{
"type":"section-title",
"hlId":"c53b76",
"children":[
"Prevention"
]
},
"children":[
{
"type":"p",
"hlId":"e3e39c",
"children":[
"Prevention is divided into preoperative, intraoperative, and postoperative measures (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t56",
"wrapId":"5",
"children":[
"Table 56"
]
}
]
},
")"
]
},
". Modifiable host factors should be optimized before surgery. If antibiotic prophylaxis is indicated, select the correct agent, dose, and time for administration (60 minutes before incision, 2 hours before incision for vancomycin or fluoroquinolones), and redose during surgery based on surgery duration and antibiotic half-life. Continuing antibiotics postoperatively does not decrease SSI incidence, even in cases of intraoperative spillage of gastrointestinal contents or presence of wound drains."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_a_id_t56"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"a3a85d",
"children":[
"Most surgical site infections occur within 30 days after surgery or within 90 days after surgery with implants."
]
},
{
"type":"keypoint",
"hlId":"872119",
"children":[
"Deep tissue, drainage, and purulent fluid should be obtained for culture in surgical site infections; superficial wound swab cultures are likely to reflect skin or wound colonization rather than the causative pathogen."
]
},
{
"type":"keypoint",
"hlId":"f60511",
"children":[
"Surgical site infection treatment requires debridement of necrotic tissue, drainage of abscesses or infected fluid, and specific antimicrobial therapy for organ or deep-space and deep incisional infections."
]
},
{
"type":"keypoint",
"hlId":"769313",
"children":[
"Optimizing modifiable risk factors before surgery (hyperglycemia control, reduction of immunosuppressive agents, cessation of tobacco use, weight loss) can help prevent surgical site infections."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_5",
"title":{
"__html":"Central Line–Associated Bloodstream Infections"
},
"titleNode":{
"type":"section-title",
"hlId":"e90d05",
"children":[
"Central Line–Associated Bloodstream Infections"
]
},
"children":[
{
"type":"p",
"hlId":"156cb0",
"children":[
"Central line–associated bloodstream infections (CLABSIs), associated with all types of central venous catheters (CVCs), are the most preventable HCAI. In the United States, CVC rates are 55% in ICU patients and 24% in non-ICU patients. Pathogens associated with CLABSIs include coagulase-negative staphylococci (20.5%), ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
" (12.3%), ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Enterococcus faecalis"
]
},
" (8.8%), non-albicans ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
" species (8.1%), ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"K. pneumoniae"
]
},
" or ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"oxytoca"
]
},
" (7.9%), ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Enterococcus faecium"
]
},
" (7%), and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida albicans"
]
},
" (6.5%). Antimicrobial resistance is a problem for many of these pathogens. CLABSI risk factors include prolonged hospitalization before catheterization, neutropenia, and reduced nurse-to-patient ratio in the ICU. Additional risk factors (modifiable) are shown in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t57",
"wrapId":"6",
"children":[
"Table 57"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_a_id_t57"
]
},
{
"type":"section",
"id":"mk19_a_id_s17_5_1",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"590882",
"children":[
"CLABSI is suspected when a patient with a CVC has bacteremia not resulting from infection at another site. Two sets of peripheral blood cultures (20 mL blood/set) should be obtained from different sites before starting antibiotics. Avoid blood cultures drawn directly from CVCs because they have a higher rate of false positivity; they may falsely identify a CLABSI and lead to unnecessary antibiotic therapy."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_5_2",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"96489b",
"children":[
"Infected CVCs should be removed; this is particularly important for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"P. aeruginosa"
]
},
", and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
" species infections. The duration of therapy for most cases of uncomplicated non–",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
" CLABSI is 7 to 14 days ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t58",
"wrapId":"7",
"children":[
"Table 58"
]
}
]
},
")"
]
},
". ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
" CLABSI is usually treated for at least 4 weeks; however, shorter-term therapy may be considered in select patients who have immediate catheter removal with resolution of fever and bacteremia within 72 hours of starting appropriate therapy and who have no implanted prosthetic devices; no evidence of endocarditis by echocardiography (preferably transesophageal), of suppurative thrombophlebitis, or of metastatic infection; and neither diabetes mellitus nor immunosuppression. Bacteremia clearance should be confirmed with follow-up blood cultures. If bacteremia persists after CVC removal and appropriate antimicrobial therapy, evaluation for a deeper source of infection, including endocarditis, should be performed. All patients with candidemia should be evaluated by an ophthalmologist to rule out the presence of candida endophthalmitis within 1 to 2 weeks."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_a_id_t58"
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_5_3",
"title":{
"__html":"Prevention"
},
"titleNode":{
"type":"section-title",
"hlId":"c53b76",
"children":[
"Prevention"
]
},
"children":[
{
"type":"p",
"hlId":"3a60de",
"children":[
"CVCs should be inserted only by experienced personnel using the insertion bundle of hand hygiene, chlorhexidine skin antisepsis of the insertion site using recommended application methods and contact time, maximal barrier precautions (mask, cap, gown, sterile gloves, large sterile drape covering patient), and optimal catheter site selection (subclavian site preferred, avoid femoral site). See ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t57",
"wrapId":"8",
"children":[
"Table 57"
]
}
]
},
" for further modifiable factors to prevent CLABSI. Insertion bundles, checklists, and staff education have significantly reduced CLABSIs. If CLABSI rates remain high despite adherence to these strategies, patient chlorhexidine bathing and antimicrobial-impregnated catheters (silver-sulfadiazine–chlorhexidine, minocycline-rifampin) may be considered. Routine CVC exchange or replacement or administration of systemic antimicrobial prophylaxis at time of insertion or during CVC use should be avoided."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_a_id_t57"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"c1fc29",
"children":[
"A central line–associated bloodstream infection should be suspected when a patient with a central venous catheter has bacteremia not resulting from infection at another site."
]
},
{
"type":"keypoint",
"hlId":"7720cd",
"children":[
"The duration of therapy for most cases of uncomplicated non–",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus aureus"
]
},
" central line–associated bloodstream infection is 7 to 14 days, although ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
" infection is usually treated for at least 4 weeks."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_6",
"title":{
"__html":"<i>Staphylococcus aureus</i> Bacteremia"
},
"titleNode":{
"type":"section-title",
"hlId":"823025",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus aureus"
]
},
" Bacteremia"
]
},
"children":[
{
"type":"p",
"hlId":"b77775",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
" is a leading cause of hospital-acquired bacteremia. Endocarditis and vertebral diskitis or osteomyelitis are two important complications of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
" bacteremia, although they are less likely when the infection is hospital acquired. The source of bacteremia and possible metastatic infection should be determined, starting with a detailed history and examination. All patients should undergo endocarditis evaluation with echocardiography, preferably transesophageal. Source control with removal or drainage of any focus of infection is important for treatment success. Blood cultures should be repeated every 2 to 4 days until results are negative to document clearance."
]
},
{
"type":"p",
"hlId":"2f74be",
"children":[
"Bacteremia caused by methicillin-sensitive ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
" (MSSA) should be treated intravenously with a penicillinase-resistant semisynthetic penicillin (such as oxacillin) or first-generation cephalosporin (such as cefazolin) at maximal doses. Vancomycin should be avoided in patients with MSSA who are not allergic to β-lactam antibiotics. Vancomycin is associated with higher rates of relapse and microbiologic failure in the treatment of MSSA bacteremia."
]
},
{
"type":"p",
"hlId":"cabdaa",
"children":[
"For methicillin-resistant ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
" (MRSA) bacteremia, vancomycin and daptomycin are the preferred antibiotics. Vancomycin trough monitoring is no longer recommended for severe MRSA infections. Instead, dosing and monitoring should be guided by the area under the curve (AUC) to minimum inhibitory concentration (MIC) ratio (AUC/MIC), which provides enhanced accuracy and safety. AUC-guided dosing requires pharmacist consultation and an AUC calculator. Patients with concomitant ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
" pneumonia should not receive daptomycin because it is inactivated by surfactant. The clinical and microbiologic response (clearance of bacteremia) determines whether to continue vancomycin or change to daptomycin when the MRSA isolate has a vancomycin minimum inhibitory concentration of ≤2 µg/mL. Persistent bacteremia may be the result of slow bactericidal activity of vancomycin, inadequate dosing, poor tissue penetration, or inadequate source control. Higher-dose daptomycin (8-10 mg/kg/d) is sometimes used if bacteremia persists despite adequate source control. Vancomycin should not be used when the isolate has a minimum inhibitory concentration greater than 2 µg/mL; daptomycin is an acceptable alternative if the isolate is susceptible. The median time to clearance of MRSA bacteremia is 7 to 9 days."
]
},
{
"type":"p",
"hlId":"93ae3a",
"children":[
"Uncomplicated infection should be treated with intravenous antibiotics for 2 weeks. Bacteremia that persists beyond 72 hours of starting appropriate antibiotic treatment suggests a complicated ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
" infection and requires additional evaluation and a longer course of antibiotics (4-6 weeks). Management of persistent MSSA and MRSA bacteremia also includes a thorough search for and removal of all foci of infection, including surgical debridement of infected wounds and abscess drainage. A new focus of infection may develop with persistent bacteremia and should always be considered in the evaluation of persistent bacteremia. Deep-seated infections (endocarditis, embolic phenomena, or vertebral osteomyelitis) require a longer course of antibiotics (4-6 weeks)."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"0bf9c1",
"children":[
"Bacteremia caused by methicillin-sensitive ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus aureus"
]
},
" (MSSA) should be treated with an intravenous penicillinase-resistant semisynthetic penicillin or first-generation cephalosporin at maximal doses; vancomycin should be avoided in patients who are not allergic to β-lactam antibiotics because it is associated with higher rates of relapse and microbiologic failure in the treatment of MSSA bacteremia."
]
},
{
"type":"keypoint",
"hlId":"92d703",
"children":[
"Vancomycin and daptomycin are the preferred antibiotics for methicillin-resistant ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus aureus"
]
},
" bacteremia, although patients with concomitant ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
" pneumonia should not receive daptomycin because it is inactivated by surfactant."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_7",
"title":{
"__html":"Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia"
},
"titleNode":{
"type":"section-title",
"hlId":"5967bd",
"children":[
"Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia"
]
},
"children":[
{
"type":"p",
"hlId":"f2d758",
"children":[
"Hospital-acquired pneumonia (HAP) is pneumonia developing more than 48 hours after hospitalization. Ventilator-associated pneumonia (VAP) is pneumonia developing 48 hours after endotracheal intubation; it occurs in 10% of patients undergoing ventilation. Half of patients with HAP develop serious complications, including respiratory failure, pleural effusion, septic shock, empyema, and kidney injury. Mechanical ventilation increases the risk of pneumonia 6-fold to 21-fold. HAP and VAP risk factors include age older than 70 years, recent abdominal or thoracic surgery, immunosuppression, and underlying chronic lung disease. Modifiable risk factors are listed in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t59",
"wrapId":"9",
"children":[
"Table 59"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_a_id_t59"
]
},
{
"type":"p",
"hlId":"50234b",
"children":[
"HAP and VAP are most commonly caused by bacteria, but viral and fungal pathogens should be considered in immunocompromised patients. The main risk factor for MRSA, antibiotic-resistant ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pseudomonas"
]
},
", or other antibiotic-resistant pathogens is intravenous antibiotic use within the past 90 days. Additional risk factors for multidrug-resistant pathogens associated with VAP are septic shock at the time of VAP, acute respiratory distress syndrome preceding VAP, 5 or more days of hospitalization before VAP, and acute kidney replacement therapy before VAP."
]
},
{
"type":"section",
"id":"mk19_a_id_s17_7_1",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"17f57b",
"children":[
"Diagnosis relies on a combination of clinical, radiographic, and microbiologic findings. A new lung infiltrate on imaging plus clinical findings, including new-onset fever (temperature >38 °C [100.4 °F]), leukocytosis or leukopenia, purulent sputum, and decline in oxygenation, suggest pneumonia. Noninvasive sampling (endotracheal aspiration) with semiquantitative sputum cultures (heavy, moderate, light, and no growth) are suggested for diagnosing VAP. Clinical findings without radiographic support suggest tracheobronchitis, which does not require antibiotic treatment."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_7_2",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"18569d",
"children":[
"Respiratory sample culture results should guide therapy for suspected HAP; a specimen from the lower respiratory tract should be obtained before starting antimicrobial therapy. However, inability to obtain a specimen should not delay therapy initiation for VAP, and empiric antimicrobial therapy should be instituted for patients with VAP pending results of noninvasive sampling with semiquantitative cultures and based on local VAP antibiograms, if available."
]
},
{
"type":"p",
"hlId":"825e10",
"children":[
"Empiric VAP regimens should include coverage for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"P. aeruginosa"
]
},
", and other gram-negative bacilli. An agent active against MRSA (vancomycin, linezolid) should be included for patients with MRSA risk factors or those in a unit with MRSA prevalence greater than 10% to 20% or unknown. Two antipseudomonal agents of different classes are recommended for empiric regimens only for patients with risk factors for resistance, with structural lung disease (bronchiectasis, cystic fibrosis), or in a unit with greater than 10% resistance to an agent being considered for monotherapy. Similar regimens are recommended for patients with HAP who are treated empirically. Antimicrobial coverage for oral anaerobes may be considered in patients with witnessed aspiration events or recent surgery but is not routinely recommended unless lung abscess or empyema is suspected. Cephalosporins should be avoided as monotherapy in settings where extended-spectrum β-lactamase (ESBL)–producing gram-negative organisms (such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"K. pneumoniae"
]
},
") are prevalent; consider a carbapenem instead. VAP caused by gram-negative organisms sensitive only to aminoglycosides or colistin may be treated with a combination of systemic and aerosolized antibiotics."
]
},
{
"type":"p",
"hlId":"1efb18",
"children":[
"Microbiologic results should be reviewed at 48 to 72 hours, and all patients should be re-evaluated for clinical improvement. Antimicrobial therapy should be de-escalated (to narrow-spectrum or oral therapy) based on microbiologic results and clinical stabilization or discontinued if the diagnosis of pneumonia is in doubt. Patients who do not improve within 72 hours of appropriate therapy should undergo investigation for infectious complications, an alternate diagnosis, or another site of infection. HAP and VAP should be treated for 7 days or less."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_7_3",
"title":{
"__html":"Prevention"
},
"titleNode":{
"type":"section-title",
"hlId":"c53b76",
"children":[
"Prevention"
]
},
"children":[
{
"type":"p",
"hlId":"ba7e80",
"children":[
"Commonly used ventilator bundles include subglottic suctioning, peptic ulcer disease and deep venous thrombosis prophylaxis, and avoiding gastric overdistention. Use of ventilator bundles has been shown to decrease VAP rates by 71%. Additional interventions are listed in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t59",
"wrapId":"10",
"children":[
"Table 59"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"10",
"contentIds":[
"mk19_a_id_t59"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"0e73a4",
"children":[
"The diagnosis of hospital-acquired and ventilator-associated pneumonia are suggested by a new lung infiltrate on imaging plus clinical findings, including new-onset fever, leukocytosis or leukopenia, purulent sputum, and decline in oxygenation."
]
},
{
"type":"keypoint",
"hlId":"87e8a8",
"children":[
"Empiric ventilator-associated pneumonia regimens should include coverage for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus aureus"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pseudomonas aeruginosa"
]
},
", and other gram-negative bacilli; an agent active against methicillin-resistant ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
" (MRSA) should be included for patients with MRSA risk factors or where MRSA prevalence exceeds 10% (or is unknown); similar regimens are recommended for empiric hospital-acquired pneumonia treatment."
]
},
{
"type":"keypoint",
"hlId":"4293e9",
"children":[
"In patients receiving mechanical ventilation, the head of the bed should be elevated 30° to 45°; a supine position, particularly in patients receiving enteral nutrition, increases the risk for developing ventilator-associated pneumonia."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_8",
"title":{
"__html":"Hospital-Acquired Infections Caused by Multidrug-Resistant Organisms"
},
"titleNode":{
"type":"section-title",
"hlId":"aed707",
"children":[
"Hospital-Acquired Infections Caused by Multidrug-Resistant Organisms"
]
},
"children":[
{
"type":"p",
"hlId":"406eba",
"children":[
"Antimicrobial resistance has been noted in nearly all bacterial pathogens. Multidrug-resistant organisms (MDROs) are most prevalent in health care settings (highest incidence in long-term acute care hospitals) but are also observed in the community. Nearly half of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
" HCAIs in the United States are methicillin resistant, about 30% of enterococci are vancomycin resistant, 20.7% of Enterobacteriaceae produce ESBL and are resistant to all β-lactam antibiotics, 3.3% of Enterobacteriaceae are resistant to carbapenems, and 14.2% of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"P. aeruginosa"
]
},
" and 43.1% of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Acinetobacter"
]
},
" species are multidrug resistant (some ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Acinetobacter"
]
},
" are resistant to nearly all antibiotics)."
]
},
{
"type":"p",
"hlId":"873a83",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida auris"
]
},
" is an emerging drug-resistant pathogen shed from patients' skin into the environment, where it can survive for weeks and be transmitted to other patients. It causes severe invasive infections, particularly in immunocompromised patients. See ",
{
"type":"cross-reference",
"target":"mk19_a_id_s8_1",
"children":[
"Fungal Infections"
]
},
" for additional information."
]
},
{
"type":"p",
"hlId":"eab946",
"children":[
"MDRO infections are difficult to treat, with mortality rates up to four times higher than infections caused by antibiotic-sensitive strains. Limiting transmission of MDROs in health care settings requires full adherence to hand hygiene protocols, contact precautions, and cleaning and disinfecting of the environment and patient care equipment. More than half of hospitalized patients receive antibiotics, a major risk for acquiring an antibiotic-resistant organism and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. difficile"
]
},
" infection. Judicious use of antimicrobial agents is increasingly important to combat the rise of MDROs and emergence of untreatable infections."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"95ccf9",
"children":[
"Multidrug-resistant organisms are most prevalent in health care settings (highest incidence in long-term acute care hospitals) but are also observed in the community."
]
},
{
"type":"keypoint",
"hlId":"0c47d3",
"hvc":true,
"children":[
"Limiting emergence and transmission of multidrug-resistant organisms in health care settings requires full adherence to hand hygiene protocols, contact precautions, cleaning and disinfecting of the environment and equipment, and judicious use of antimicrobial agents."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_9",
"title":{
"__html":"Needlestick Injury"
},
"titleNode":{
"type":"section-title",
"hlId":"da4d8a",
"children":[
"Needlestick Injury"
]
},
"children":[
{
"type":"p",
"hlId":"ca9aa2",
"children":[
"Needlestick and sharps injuries increase the risk for health care personnel (HCP) of acquiring blood-borne diseases such as HIV, hepatitis B (HBV), and hepatitis C (HCV). Most injuries occur with hollow-bore needles, which confer a higher risk of blood-borne pathogen transmission. Personal protective equipment and sharps safety practices minimize the risk, as does avoiding workplace fatigue and under-resourcing of work environments. Additionally, it is recommended that all HCP be immunized against HBV."
]
},
{
"type":"p",
"hlId":"801d02",
"children":[
"Needlestick or sharps injuries should immediately be washed with soap and water, and the event should be reported. The source patient should be assessed for HBV, HCV, and HIV. The exposed HCP should seek immediate treatment and receive baseline testing for HIV and for HCV with anti-HCV with reflex to HCV RNA within 48 hours of exposure; those with an initial positive result should be referred for treatment of pre-existing infection."
]
},
{
"type":"p",
"hlId":"53e45e",
"children":[
"Postexposure prophylaxis management for HBV is outlined in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t70",
"wrapId":"11",
"children":[
"Table 70"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"11",
"contentIds":[
"mk19_a_id_t70"
]
},
{
"type":"p",
"hlId":"f4e850",
"children":[
"Management of HCV exposure involves monitoring and timely diagnosis and treatment. Follow-up testing of HCP is indicated if the source patient is positive for HCV or status is unknown or if HCV RNA testing is unavailable. An HCV RNA at 3 to 6 weeks following exposure is recommended; if negative, a follow-up anti-HCV with reflex to HCV RNA at 4 to 6 months following exposure is advised. A positive HCV RNA test at any point indicates referral for treatment."
]
},
{
"type":"p",
"hlId":"792d06",
"children":[
"Postexposure prophylaxis for HIV (PEP) should be offered to all exposed HCP when the source patient is positive or reasonable suspicion exists for HIV; therapy can be discontinued if the test returns negative unless acute HIV infection is a concern. PEP should be initiated as soon as possible, preferably within a few hours. The preferred PEP regimen is raltegravir plus tenofovir disoproxil fumarate and emtricitabine for 4 weeks. Follow-up HIV testing occurs at 6 weeks, 3 months, and 6 months after exposure; however, if a fourth-generation antigen-antibody assay is used throughout monitoring, follow-up testing can occur at 6 weeks and 4 months."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"8a122d",
"children":[
"The source patient should be assessed for hepatitis B and C and HIV, and exposed health care personnel should seek immediate treatment and receive baseline testing for HIV and hepatitis C."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s17_10",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Allegranzi B, Bischoff P, de Jonge S, et al; WHO Guidelines Development Group. New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis. 2016;16:e276-e287. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27816413",
"target":"_blank"
},
"children":[
"PMID: 27816413"
]
},
" doi:10.1016/S1473-3099(16)30398-X"
]
},
{
"type":"reference",
"children":[
"Bassetti M, Poulakou G, Ruppe E, et al. Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med. 2017;43:1464-1475. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28733718",
"target":"_blank"
},
"children":[
"PMID: 28733718"
]
},
" doi:10.1007/s00134-017-4878-x"
]
},
{
"type":"reference",
"children":[
"Hassoun A, Linden PK, Friedman B. Incidence, prevalence, and management of MRSA bacteremia across patient populations; a review of recent developments in MRSA management and treatment. Crit Care. 2017;21:211. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28807042",
"target":"_blank"
},
"children":[
"PMID: 28807042"
]
},
" doi:10.1186/s13054-017-1801-3"
]
},
{
"type":"reference",
"children":[
"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61-e111. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27418577",
"target":"_blank"
},
"children":[
"PMID: 27418577"
]
},
" doi:10.1093/cid/ciw353"
]
},
{
"type":"reference",
"children":[
"Meddings J, Saint S, Fowler KE, et al. The Ann Arbor Criteria for appropriate urinary catheter use in hospitalized medical patients: results obtained by using the RAND/UCLA appropriateness method. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M14-1304",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2015;162:S1-34. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25938928",
"target":"_blank"
},
"children":[
"PMID: 25938928"
]
}
]
},
{
"type":"reference",
"children":[
"Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus aureus"
]
},
" infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2020;71:1361-1364. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32658968",
"target":"_blank"
},
"children":[
"PMID: 32658968"
]
},
" doi:10.1093/cid/ciaa303"
]
},
{
"type":"reference",
"children":[
"Septimus EJ, Moody J. Prevention of device-related healthcare-associated infections. F1000Res. 2016;5. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26918162",
"target":"_blank"
},
"children":[
"PMID: 26918162"
]
},
" doi:10.12688/f1000research.7493.1"
]
},
{
"type":"reference",
"children":[
"Shuman E, Chenoweth CE. Urinary catheter-associated infections. Infect Dis Clin North Am. 2018 Dec;32(4):885-897. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30241712",
"target":"_blank"
},
"children":[
"PMID: 30241712"
]
},
" doi:10.1016/j.idc.2018.07.002"
]
},
{
"type":"reference",
"children":[
"Weiner-Lastinger LM, Abner S, Edwards JR, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017. Infect Control Hosp Epidemiol. 2020;41:1-18. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31767041",
"target":"_blank"
},
"children":[
"PMID: 31767041"
]
},
" doi:10.1017/ice.2019.296"
]
},
{
"type":"reference",
"children":[
"Yokoe DS, Anderson DJ, Berenholtz SM, Calfee DP, Dubberke ER, Ellingson KD, et al. A compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates. Infect Control Hosp Epidemiol. 2014;35 Suppl 2:S21-31. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25376067",
"target":"_blank"
},
"children":[
"PMID: 25376067"
]
},
" doi:10.1017/s0899823x00193833"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_a_id_t53":{
"id":"mk19_a_id_t53",
"number":53,
"bookId":"id",
"title":{
"__html":"Transmission-Based Precautions<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"872649",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 53. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t53"
}
]
},
"Transmission-Based Precautions",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff7516",
"class":"col hd l",
"children":[
"Precaution Type"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b670b8",
"class":"col hd l",
"children":[
"Indications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"409a66",
"class":"col hd l",
"children":[
"Precaution"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff7c0f",
"class":"col hd l",
"children":[
"Examples"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5c1be1",
"class":"cell txt l",
"children":[
"Airborne"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e8135d",
"class":"cell txt l",
"children":[
"Organisms transmitted from respiratory tract by small droplet nuclei (≤5 microns) that travel long distances on air currents"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8766d0",
"class":"cell txt l",
"children":[
"Airborne infection isolation room (negative-pressure room); HCP wear fit-tested N95 respirator ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_a_id_f34",
"wrapId":null,
"children":[
"Figure 34"
]
}
]
},
")"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f3d39d",
"class":"cell txt l",
"children":[
"Chickenpox (plus contact precautions), tuberculosis, measles, SARS-CoV-2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bbaff1",
"class":"cell txt l",
"children":[
"Contact"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"946bf6",
"class":"cell txt l",
"children":[
"Organisms transmitted by direct or indirect contact"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b507ba",
"class":"cell txt l",
"children":[
"Single room; gloves and gown for HCP entering room"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8bca6d",
"class":"cell txt l",
"children":[
"Multidrug-resistant organisms (such as MRSA, VRE, ESBL-producing gram-negative organisms, CRE), ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Clostridioides difficile"
]
},
", rotavirus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"180907",
"class":"cell txt l",
"children":[
"Droplet"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d951e1",
"class":"cell txt l",
"children":[
"Organisms transmitted from respiratory tract by large droplet nuclei (>5 microns) that travel less than 3 feet on air currents"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"48ab88",
"class":"cell txt l",
"children":[
"Single room; HCP wear face or surgical mask when within 3 feet of patient"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"beb477",
"class":"cell txt l",
"children":[
"Influenza, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Bordetella pertussis"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Neisseria meningitidis"
]
},
" for first 24 hours of therapy, mumps"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CRE = carbapenem-resistant Enterobacteriaceae; ESBL = extended-spectrum β-lactamase; HCP = health care personnel; MRSA = methicillin-resistant ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus aureus"
]
},
"; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; VRE = vancomycin-resistant enterococci."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Some organisms and infections require a combination of transmission-based precautions (adenovirus: contact and droplet; disseminated varicella-zoster virus: airborne and contact; SARS-CoV-2: airborne and contact)."
]
]
},
"mk19_a_id_t54":{
"id":"mk19_a_id_t54",
"number":54,
"bookId":"id",
"title":{
"__html":"Appropriate Indications for Use of Indwelling Urinary Catheters "
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"2a5a7e",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 54. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t54"
}
]
},
"Appropriate Indications for Use of Indwelling Urinary Catheters "
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b1583",
"class":"col hd l",
"children":[
"Indication"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5dc543",
"class":"cell txt l",
"children":[
"Management of acute urinary retention without bladder outlet obstruction"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a39150",
"class":"cell txt l",
"children":[
"Management of acute urinary retention with bladder outlet obstruction not related to infection or trauma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8a6716",
"class":"cell txt l",
"children":[
"Management of chronic urinary retention with bladder outlet obstruction when ISC is not feasible"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b99a99",
"class":"cell txt l",
"children":[
"Management of stage III or IV or unstageable pressure ulcers that cannot be kept clear of urinary incontinence despite other urinary management strategies (e.g., barrier creams, absorbent pads, prompted toileting, non-indwelling catheters)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6b1079",
"class":"cell txt l",
"children":[
"Hourly measurement of urine volume required to provide treatment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6ef9a",
"class":"cell txt l",
"children":[
"Daily measurement of urine volume required to provide treatment when it cannot be assessed by other volume (e.g., daily weighing, physical examination) and urine collection (e.g., urinal, bedside commode, bedpan, external catheter, ISC) strategies"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3836d5",
"class":"cell txt l",
"children":[
"Collection of a single 24-hour urine sample needed for diagnostic test that cannot be obtained by other urine collection strategies"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"df1b5c",
"class":"cell txt l",
"children":[
"Reduction in instances of acute, severe pain with movement when other urine management strategies are difficult"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"35358a",
"class":"cell txt l",
"children":[
"Improvement in comfort when urine collection by catheter addresses patient and family goals in a dying patient"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a4ab9",
"class":"cell txt l",
"children":[
"Management of gross hematuria with blood clots in urine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2bfd45",
"class":"cell txt l",
"children":[
"Management of clinical condition for which ISC or external catheter is appropriate but placement is difficult or bladder emptying is inadequate for the patient with non-indwelling strategies"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ISC = intermittent straight catheterization."
]
]
},
"mk19_a_id_t55":{
"id":"mk19_a_id_t55",
"number":55,
"bookId":"id",
"title":{
"__html":"Prevention of Catheter-Associated Urinary Tract Infection"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"6438c5",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 55. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t55"
}
]
},
"Prevention of Catheter-Associated Urinary Tract Infection"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"190160",
"class":"col hd l",
"children":[
"Period"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ced8b5",
"class":"col hd l",
"children":[
"Preventive Measures"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6718bc",
"class":"cell txt l",
"children":[
"Before catheterization"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"941e68",
"class":"cell txt l",
"children":[
"Avoid catheterization whenever possible"
]
},
" ",
{
"type":"p",
"hlId":"2ff02c",
"class":"cell txt l",
"children":[
"Insert catheter only for appropriate indications"
]
},
" ",
{
"type":"p",
"hlId":"a4fe19",
"class":"cell txt l",
"children":[
"Consider alternatives, such as condom catheters and intermittent catheterization"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"30c47a",
"class":"cell txt l",
"children":[
"At time of catheter insertion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2655ff",
"class":"cell txt l",
"children":[
"Ensure that only properly trained persons insert and maintain catheters"
]
},
" ",
{
"type":"p",
"hlId":"90b064",
"class":"cell txt l",
"children":[
"Adhere to hand hygiene practices and standard (or appropriate isolation) precautions according to CDC HICPAC/WHO guidelines"
]
},
" ",
{
"type":"p",
"hlId":"08c0d7",
"class":"cell txt l",
"children":[
"Use proper aseptic techniques and sterile equipment when inserting the catheter (acute care setting)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1865c0",
"class":"cell txt l",
"children":[
"After catheter insertion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"770e8c",
"class":"cell txt l",
"children":[
"Promote early catheter removal whenever possible"
]
},
" ",
{
"type":"p",
"hlId":"2c7e8a",
"class":"cell txt l",
"children":[
"Secure the catheter"
]
},
" ",
{
"type":"p",
"hlId":"df5e2b",
"class":"cell txt l",
"children":[
"Use aseptic technique when handling the catheter, including for sample collection from the designated port (not collecting bag)"
]
},
" ",
{
"type":"p",
"hlId":"7f85b3",
"class":"cell txt l",
"children":[
"Maintain a closed drainage system"
]
},
" ",
{
"type":"p",
"hlId":"3288b1",
"class":"cell txt l",
"children":[
"Avoid unnecessary system disconnections"
]
},
" ",
{
"type":"p",
"hlId":"20a038",
"class":"cell txt l",
"children":[
"Maintain unobstructed urine flow"
]
},
" ",
{
"type":"p",
"hlId":"f6b4c7",
"class":"cell txt l",
"children":[
"Keep the collecting bag below the level of the bladder and off the floor"
]
},
" ",
{
"type":"p",
"hlId":"445fbc",
"class":"cell txt l",
"children":[
"Empty the collecting bag regularly, using a separate collecting container for each patient"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CDC = Centers for Disease Control and Prevention; HICPAC = Healthcare Infection Control Practices Advisory Committee; WHO = World Health Organization."
]
]
},
"mk19_a_id_t56":{
"id":"mk19_a_id_t56",
"number":56,
"bookId":"id",
"title":{
"__html":"Mitigation of Risk Factors for Surgical Site Infection"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"d2f8d4",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 56. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t56"
}
]
},
"Mitigation of Risk Factors for Surgical Site Infection"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8a7945",
"class":"col hd l",
"children":[
"Risk Factor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c143a2",
"class":"col hd l",
"children":[
"Intervention"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"65e677",
"class":"cell txt l",
"children":[
"Hyperglycemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"43cbd9",
"class":"cell txt l",
"children":[
"Maintain blood glucose level ≤180 mg/dL (10 mmol/L) during first 48 hours after surgery"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8c9c78",
"class":"cell txt l",
"children":[
"Immunosuppression"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f1fd54",
"class":"cell txt l",
"children":[
"Reduce doses of immunosuppressive agents"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"209c07",
"class":"cell txt l",
"children":[
"Tobacco use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c1b4b",
"class":"cell txt l",
"children":[
"Cease 30 days before surgery"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9f8251",
"class":"cell txt l",
"children":[
"Obesity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8cd84a",
"class":"cell txt l",
"children":[
"Weight loss"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2bf750",
"class":"cell txt l",
"children":[
"Malnutrition"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c5ae5",
"class":"cell txt l",
"children":[
"Optimize nutritional status before surgery"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c91df5",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus aureus"
]
},
" nasal carriage"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"73b32a",
"class":"cell txt l",
"children":[
"For cardiovascular and orthopedic surgeries, test for nasal carriage 1-2 weeks before"
]
},
" ",
{
"type":"p",
"hlId":"aa2ea0",
"class":"cell txt l",
"children":[
"If positive, decolonize using intranasal 2% mupirocin ointment with or without chlorhexidine body wash"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cdb268",
"class":"cell txt l",
"children":[
"Skin preparation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aa3288",
"class":"cell txt l",
"children":[
"Shower the night before (soap or an antiseptic)"
]
},
" ",
{
"type":"p",
"hlId":"3913ab",
"class":"cell txt l",
"children":[
"Use an alcohol-based chlorhexidine scrub at incision site"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6015a2",
"class":"cell txt l",
"children":[
"Hair removal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b2eb25",
"class":"cell txt l",
"children":[
"Do not shave site of incision"
]
},
" ",
{
"type":"p",
"hlId":"b64504",
"class":"cell txt l",
"children":[
"If hair must be removed, it should be clipped as close to time of incision as possible"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7adb45",
"class":"cell txt l",
"children":[
"Hypothermia and hypovolemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1228b",
"class":"cell txt l",
"children":[
"Maintain perioperative normothermia (temperature >36 °C [96.8 °F]) and adequate volume replacement to ensure maximum tissue oxygen delivery"
]
},
" ",
{
"type":"p",
"hlId":"9f8327",
"class":"cell txt l",
"children":[
"2 °C (3.6 °F) decrease in body temperature associated with threefold increase in surgical site infection"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"76e80e",
"class":"cell txt l",
"children":[
"Incision dressing"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2eee6f",
"class":"cell txt l",
"children":[
"Primarily closed incision covered with sterile dressing for 24-48 hours"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_a_id_t57":{
"id":"mk19_a_id_t57",
"number":57,
"bookId":"id",
"title":{
"__html":"Mitigation of Risk Factors for Central Line–Associated Bloodstream Infections"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"c69829",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 57. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t57"
}
]
},
"Mitigation of Risk Factors for Central Line–Associated Bloodstream Infections"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d20d5c",
"class":"col hd l",
"children":[
"Modifiable (Extrinsic) Risk Factor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c143a2",
"class":"col hd l",
"children":[
"Intervention"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dc909d",
"class":"cell txt l",
"children":[
"Prolonged catheterization"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"80cb40",
"class":"cell txt l",
"children":[
"Daily review of continued need for CVC"
]
},
" ",
{
"type":"p",
"hlId":"05b7f7",
"class":"cell txt l",
"children":[
"Discontinue as soon as practical"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7d3ba1",
"class":"cell txt l",
"children":[
"Multiple CVCs (increases risk 3.4-fold)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6eb9c6",
"class":"cell txt l",
"children":[
"Minimize the number of CVCs as much as practical"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4721a",
"class":"cell txt l",
"children":[
"Multilumen CVC"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a52c69",
"class":"cell txt l",
"children":[
"Use a catheter with the minimum number of lumens needed"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f87cd9",
"class":"cell txt l",
"children":[
"Femoral vein catheterization; particularly in patients with obesity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"04ed3f",
"class":"cell txt l",
"children":[
"Use subclavian site when possible"
]
},
" ",
{
"type":"p",
"hlId":"a4bc46",
"class":"cell txt l",
"children":[
"Use ultrasonographic guidance for internal jugular catheter insertion"
]
},
" ",
{
"type":"p",
"hlId":"c30411",
"class":"cell txt l",
"children":[
"Remove femoral vein CVCs as soon as practical; relocate to another site (e.g., subclavian, internal jugular vein) when possible"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3feaea",
"class":"cell txt l",
"children":[
"Heavy microbial colonization at insertion site and catheter hub"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"617752",
"class":"cell txt l",
"children":[
"Chlorhexidine skin antisepsis at time of insertion"
]
},
" ",
{
"type":"p",
"hlId":"907d49",
"class":"cell txt l",
"children":[
"Chlorhexidine-impregnated dressing"
]
},
" ",
{
"type":"p",
"hlId":"b3469f",
"class":"cell txt l",
"children":[
"Daily chlorhexidine bathing of patients in ICU"
]
},
" ",
{
"type":"p",
"hlId":"6dbdad",
"class":"cell txt l",
"children":[
"Minimize catheter access"
]
},
" ",
{
"type":"p",
"hlId":"0a7a9e",
"class":"cell txt l",
"children":[
"Hand hygiene before manipulation of IV system; use aseptic technique for all IV access"
]
},
" ",
{
"type":"p",
"hlId":"85007a",
"class":"cell txt l",
"children":[
"Use disinfection caps or disinfect catheter hub and needleless connectors (“scrub the hub”) before accessing"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7bd02e",
"class":"cell txt l",
"children":[
"Lack of maximal sterile barriers for insertion and breaks in aseptic technique"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"97c6fe",
"class":"cell txt l",
"children":[
"Follow CVC insertion bundle"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a86d02",
"class":"cell txt l",
"children":[
"Emergent insertion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a998e2",
"class":"cell txt l",
"children":[
"When adherence to aseptic technique cannot be ensured, replace CVC as soon as possible (at least within 48 hours) to a new site"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8d7db1",
"class":"cell txt l",
"children":[
"Total parenteral nutrition"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d7b0be",
"class":"cell txt l",
"children":[
"Consider other options for delivering nutrition when possible"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CVC = central venous catheter; IV = intravenous."
]
]
},
"mk19_a_id_t58":{
"id":"mk19_a_id_t58",
"number":58,
"bookId":"id",
"title":{
"__html":"Management of Central Venous Catheter–Related Bloodstream Infection Based on Pathogen<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"13a39d",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 58. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t58"
}
]
},
"Management of Central Venous Catheter–Related Bloodstream Infection Based on Pathogen",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e69d46",
"class":"col hd l",
"children":[
"Organism"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4c4ac0",
"class":"col hd l",
"children":[
"Treatment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"fec019",
"class":"col hd l",
"children":[
"Uncomplicated",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea7bf5",
"class":"cell txt l",
"children":[
"Coagulase-negative staphylococci"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"368e12",
"class":"cell txt l",
"children":[
"Remove catheter, antimicrobial therapy for 5-7 days"
]
},
" ",
{
"type":"p",
"hlId":"7f2e29",
"class":"cell txt l",
"children":[
"If catheter is not removed, systemic antimicrobials and antimicrobial lock treatment",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
" for 10-14 days"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2f6133",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus aureus"
]
},
" (no active malignancy or immunosuppression)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"859e2c",
"class":"cell txt l",
"children":[
"Remove catheter, antimicrobials for ≥14 days (usually 4 weeks)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4b8869",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Enterococcus"
]
},
" species"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"adb311",
"class":"cell txt l",
"children":[
"Remove catheter, antimicrobials for 7-14 days"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f0f1b",
"class":"cell txt l",
"children":[
"Gram-negative bacilli"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"adb311",
"class":"cell txt l",
"children":[
"Remove catheter, antimicrobials for 7-14 days"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"361271",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
" species (no retinitis)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"91c332",
"class":"cell txt l",
"children":[
"Remove catheter, antifungal agent for 14 additional days after first negative blood culture"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"565614",
"class":"col hd l",
"children":[
"Complicated"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d2480b",
"class":"cell txt l",
"children":[
"Suppurative thrombophlebitis, endocarditis, osteomyelitis, other site of metastatic or deep-seated infection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"00a4f5",
"class":"cell txt l",
"children":[
"Remove catheter, antimicrobials for 4-6 weeks (6-8 weeks for osteomyelitis)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Short-term catheters."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Bloodstream infection and fever resolve in 72 hours, no intravascular hardware, no endocarditis or suppurative thrombophlebitis."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Antimicrobial solution (such as vancomycin) instilled into the lumen of a catheter and removed after a specified period of time."
]
]
},
"mk19_a_id_t59":{
"id":"mk19_a_id_t59",
"number":59,
"bookId":"id",
"title":{
"__html":"Mitigation of Risk Factors for Ventilator-Associated Pneumonia"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"1e02f7",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 59. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t59"
}
]
},
"Mitigation of Risk Factors for Ventilator-Associated Pneumonia"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8a7945",
"class":"col hd l",
"children":[
"Risk Factor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c143a2",
"class":"col hd l",
"children":[
"Intervention"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d6c524",
"class":"cell txt l",
"children":[
"Mechanical ventilation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37b8be",
"class":"cell txt l",
"children":[
"Consider noninvasive, positive-pressure ventilation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"41da10",
"class":"cell txt l",
"children":[
"Sedation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d27532",
"class":"cell txt l",
"children":[
"Minimize"
]
},
" ",
{
"type":"p",
"hlId":"a9ae6d",
"class":"cell txt l",
"children":[
"Intermittent infusions or daily interruption and daily assessment of readiness for extubation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5ef9f4",
"class":"cell txt l",
"children":[
"Supine position"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6a60af",
"class":"cell txt l",
"children":[
"Risk highest for patients receiving enteral nutrition"
]
},
" ",
{
"type":"p",
"hlId":"73eba6",
"class":"cell txt l",
"children":[
"Elevate head of bed 30°-45°"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9855b0",
"class":"cell txt l",
"children":[
"Oropharyngeal colonization"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"74e1b8",
"class":"cell txt l",
"children":[
"Daily oral care; oral care with chlorhexidine may be beneficial in some patients"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c276bd",
"class":"cell txt l",
"children":[
"Physical conditioning"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7550d6",
"class":"cell txt l",
"children":[
"Facilitate early mobility (speeds extubation)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e32cac",
"class":"cell txt l",
"children":[
"Reintubation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37b8be",
"class":"cell txt l",
"children":[
"Consider noninvasive, positive-pressure ventilation"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_a_id_t70":{
"id":"mk19_a_id_t70",
"number":70,
"bookId":"id",
"title":{
"__html":"Postexposure Management of Health Care Personnel following Percutaneous or Mucosal Exposure to Hepatitis B"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"b322ec",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 70. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t70"
}
]
},
"Postexposure Management of Health Care Personnel following Percutaneous or Mucosal Exposure to Hepatitis B"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"13d75a",
"class":"col hd l",
"children":[
"HCP Status",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"41e78b",
"class":"col hd l",
"children":[
"Source Patient HBsAg + or Status Unknown"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"778449",
"class":"col hd l",
"children":[
"Source Patient HBsAg −"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aa4281",
"class":"cell txt l",
"children":[
"Vaccine responder",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f51a49",
"class":"cell txt l",
"children":[
"No action needed"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f51a49",
"class":"cell txt l",
"children":[
"No action needed"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0e20b3",
"class":"cell txt l",
"children":[
"Vaccine nonresponder",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
" after 6 doses"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"313d5c",
"class":"cell txt l",
"children":[
"HBIG",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
" × 2 separated by 1 month"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f51a49",
"class":"cell txt l",
"children":[
"No action needed"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ac0fdf",
"class":"cell txt l",
"children":[
"If vaccine response unknown, test HCP"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"186cd1",
"class":"cell txt li",
"children":[
"Anti-HBs <10 mU/mL"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c404a2",
"class":"cell txt l",
"children":[
"HBIG",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
" × 1"
]
},
" ",
{
"type":"p",
"hlId":"df5e18",
"class":"cell txt l",
"children":[
"Initiate revaccination"
]
},
" ",
{
"type":"p",
"hlId":"01d5cc",
"class":"cell txt l",
"children":[
"Postvaccination serologic testing",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"df5e18",
"class":"cell txt l",
"children":[
"Initiate revaccination"
]
},
" ",
{
"type":"p",
"hlId":"01d5cc",
"class":"cell txt l",
"children":[
"Postvaccination serologic testing",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ece4a6",
"class":"cell txt li",
"children":[
"Anti-HBs ≥10 mU/mL"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f51a49",
"class":"cell txt l",
"children":[
"No action needed"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f51a49",
"class":"cell txt l",
"children":[
"No action needed"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"97cfbb",
"class":"cell txt l",
"children":[
"Unvaccinated or incompletely vaccinated"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c404a2",
"class":"cell txt l",
"children":[
"HBIG",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
" × 1"
]
},
" ",
{
"type":"p",
"hlId":"376c24",
"class":"cell txt l",
"children":[
"Complete vaccination"
]
},
" ",
{
"type":"p",
"hlId":"01d5cc",
"class":"cell txt l",
"children":[
"Postvaccination serologic testing",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"376c24",
"class":"cell txt l",
"children":[
"Complete vaccination"
]
},
" ",
{
"type":"p",
"hlId":"01d5cc",
"class":"cell txt l",
"children":[
"Postvaccination serologic testing",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
}
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"anti-HBs = antibody to hepatitis B surface antigen; HBIG = hepatitis B immune globulin; HBsAg = hepatitis B surface antigen; HCP = health care personnel."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"HCP who have anti-HBs <10 mU/mL, or who are unvaccinated or incompletely vaccinated, and sustain an exposure to a source patient who is HBsAg-positive or has unknown HBsAg status, should undergo baseline testing for HBV infection as soon as possible after exposure, and follow-up testing approximately 6 months later. Initial baseline tests consist of total anti–hepatitis B core antigen (anti-HBc); testing at approximately 6 months consists of HBsAg and total anti-HBc."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Documented response after complete vaccination series and/or anti-HBs ≥10 mU/mL."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"A nonresponder is defined as a person with anti-HBs <10 mU/mL after ≥6 doses of hepatitis B vaccine."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"HBIG should be administered intramuscularly as soon as possible after exposure when indicated. The effectiveness of HBIG when administered >7 days after percutaneous, mucosal, or nonintact skin exposures is unknown."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
},
"Should be performed 1 to 2 months after the last dose of the HepB vaccine series (and 4-6 months after administration of HBIG to avoid detection of passively administered anti-HBs) using a quantitative method that allows detection of the protective concentration of anti-HBs (≥10 mU/mL)."
],
[
"Adapted from Schillie S, Murphy TV, Sawyer M, et al; Centers for Disease Control and Prevention (CDC). CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep. 2013;62:1-19. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/24352112",
"target":"_blank"
},
"children":[
"PMID: 24352112"
]
}
]
]
}
}
}